deltatrials
Terminated PHASE2 INTERVENTIONAL 7-arm NCT01917006

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation

Sponsor: Allergan

Conditions Premature Ejaculation
Interventions Normal Saline OnabotulinumtoxinA
Updated 8 times since 2017 Last updated: Sep 21, 2018 Started: Aug 7, 2013 Primary completion: Aug 15, 2017 Completion: Aug 15, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic business decision was made to terminate the program. There were no safety concerns.

Other terminated trials from Allergan

See all terminations from Allergan

This PHASE2 trial investigates Premature Ejaculation and is currently terminated or withdrawn. Allergan leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotRecruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotTerminated~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotTerminated~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Nov 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Nov 2018 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allergan
Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations